Sorafenib News and Research

RSS

Sorafenib (Nexavar) is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC).

Researchers find new mechanism of action of the anti-cancer drug sorafenib

Virginia Commonwealth University Massey Cancer Center researchers have uncovered a new mechanism of action of the anti-cancer drug sorafenib, which could stimulate the development of novel regimens in which it is combined with other molecularly targeted agents for patients with blood cancers and solid tumors.

15 Jun 2007

Results of phase II studies of pazopanib

GlaxoSmithKline (GSK) has announced results from ongoing Phase II studies of pazopanib in advanced or metastatic renal cell carcinoma (RCC) and ovarian cancer.

5 Jun 2007

Liver cancer drug Nexavar, a major breakthrough

A trial of an experimental drug to treat advanced liver cancer has helped extend patients lives by as much as three months.

4 Jun 2007

FDA approves Torisel (temsirolimus) for advanced kidney cancer

The U.S. Food and Drug Administration (FDA) hasapproved Torisel (temsirolimus) for the treatment of a certain type of advanced kidney cancer known as renal cell carcinoma.

1 Jun 2007

Nexavar approved in Europe for treatment of advanced kidney cancer

Bayer Pharmaceuticals Corporation and Onyx Pharmaceuticals, Inc have announced that the European Commission has granted marketing authorization to Nexavar (sorafenib) tablets for the treatment of patients with advanced renal cell carcinoma.

24 Jul 2006

New treatment for chronic eosinophilic leukemia

Leukemia - or cancer of the bone marrow - strikes some 700 Belgians each year. Chronic Eosinophilic Leukemia (CEL), a specific form of leukemia, is currently treated with Glivec.

10 May 2006

Therapy for metastatic renal cell carcinoma remains inadequate

The recent FDA approvals of the tyrosine kinase inhibitors sorafenib and sunitinib based on their activity in metastatic renal cell carcinoma have excited the medical oncology community

9 Mar 2006

Targeted cancer therapies: Another step forward

While it is clear that the treatment of cancer has already begun to undergo a paradigm shift with the inclusion of innovative targeted therapies into current regimens, it would be wrong to assume these products will entirely replace traditional chemotherapy as the standard treatment for cancer sufferers.

22 Dec 2005

Targeted cancer therapies: Another step forward

22 Dec 2005

Evaluation of BAY 43-9006 (Sorafenib) for pancreatic cancer

Oncologists from USC/Norris Comprehensive Cancer Center are running tests on a new pancreatic cancer drug that targets the cancer from two directions.

13 Jan 2005